Stephanie Meyer Email & Phone Number

Brisbane, California, United States

• Spearheaded the restart of lab operations. Created and executed plans to meet timelines to bring lab back to functionality within 3 months. Handled move of capital equipment and calibrations of all instruments..
• Managed service contracts and maintained calendar of operations.
• Began EH&S officer and training.
• Routinely tested patient samples for biomarkers in the QSant urine test.
• Point of contact for patient biopsy slide digitization process with CRO.
• Familiarity with Salesforce, EDC entry, and handling of patient samples.

Brisbane, California, United States

• Managed corporate biospecimen repository.
• Primary liaison for multiple external research partners for inbound and outbound transfer of specimens.
• Designed and implemented procedures for inventory management and tracking.

Brisbane, California, United States

• Optimized next-generation ELISA-based biomarker tests for kidney health.
• Performed proof-of-concept studies for novel biomarker assays.

South San Francisco, California, United States

• Lead for manufacture of nanofiltration membranes and membrane characterization.
• Trained 4 employees
• Spearheaded implementation of quality control systems

• R&D project representative at interdepartmental bi-weekly meetings. Presented results regulary.
• Developed multiple Receptor Tyrosine Kinase assays and scaled for HTS screening campaigns. Performed cell-based assays looking at GPCR agonists and antagonists.
• Mentored newer teammates in assay development and laboratory techniques.

• Developed, validated, and screened compound libraries for 2nd generation ranolazine (RANEXA) evaluation program. Original Ranexa product sales in 2019 totaled $929 million.
• Established competitive binding assay for the adenosine A2a receptor and adapted single tube radioactive assays to 96-well format. Screening led to novel A2a receptor agonist that became FDA approved product Lexiscan®.
• Purified the 20S proteasome from bovine brain to homogeneity and established a set of validated fluorogenic assays for the five catalytic activities. Identified a novel family of inhibitors specific for the.
• Performed compound dosing of mice for in vivo studies of inflammation

• Tested peptidomimetic compounds in rat liver homogenates and S9 fractions. Extracted metabolites from extracellular matrices and characterized by HPLC.
• Performed intraperitoneal compound dosing in mice.
• Grew Caco-2 cells without antibiotics via aseptic technique.
• Executed active and passive membrane transport assays with Caco-2 cell membrane monolayers. Tested monolayer integrity with TEER measurements.

Certificate, Product Management

Ethics And Human Subjects Protection: A Comprehensive Introduction, Clinical Sample Handling

Bs, Biochemistry

Classes In: Clinical Pharmacokinetics, Project Management, Essentials Of Business, Marketing